middl
east
respiratori
syndrom
mer
respiratori
diseas
caus
mer
coronaviru
lack
vaccin
variou
studi
investig
therapeut
efficaci
antivir
drug
support
remedi
systemat
literatur
search
databas
conduct
screen
relev
articl
studi
report
inform
treatment
mer
coronaviru
infect
extract
analyz
despit
receiv
treatment
ribavirin
plu
ifn
case
fatal
rate
high
ifntreat
group
exactli
patient
tion
rang
support
antivir
therapi
two
vitro
studi
suggest
possibl
efficaci
effect
interferon
ribavirin
treatment
mer
infect
consequ
investig
examin
efficaci
drug
anim
studi
potenti
benefit
antivir
treatment
vitro
anim
studi
persuad
clinician
question
feasibl
applic
approach
human
therefor
aim
recapitul
evid
human
publish
data
mer
clinic
manag
systemat
review
metaanalysi
summar
efficaci
safeti
current
appli
therapeut
defin
risk
factor
associ
outcom
result
may
provid
better
approach
compat
manag
fatal
consequ
mer
infect
risk
impos
recent
outbreak
dens
popul
area
studi
perform
accord
recommend
prefer
report
item
systemat
review
metaanalys
develop
protocol
method
regist
intern
prospect
regist
systemat
review
prospero
refer
june
conduct
systemat
search
remov
duplic
three
train
review
assign
independ
screen
titl
abstract
refer
gener
aforement
search
strategi
basi
follow
inclus
exclus
criteria
inclus
criteria
studi
give
inform
treatment
merscov
infect
b
type
studi
design
includ
c
restrict
made
respect
languag
age
area
exclus
criteria
data
could
reliabl
extract
b
data
set
consid
overlap
c
studi
publish
book
chapter
thesi
letter
confer
paper
poster
editori
e
anim
vitro
studi
three
review
compar
screen
result
discuss
differ
consensu
reach
discuss
extract
data
includ
public
year
year
research
countri
citi
patient
year
subject
recruit
studi
design
particip
enrol
data
collect
method
baselin
characterist
treatment
diagnost
method
merscov
time
admiss
treatment
start
treatment
merscov
outcom
surviv
work
conduct
investig
evalu
refer
independ
disagr
discuss
reach
consensu
supervisor
qualiti
includ
clinic
data
assess
use
care
statement
case
report
metric
tool
nonrandom
studi
three
review
assign
assess
includ
refer
independ
mortal
rate
treat
dichotom
variabl
respect
confidenti
interv
ci
statist
heterogen
assess
use
statist
assum
influenti
greater
p
fixedeffect
model
use
evid
heterogen
studi
metaanalysi
perform
use
data
analysi
statist
softwar
stata
develop
statacorp
fisher
exact
chisquar
appropri
mannwhitney
u
test
use
categor
continu
variabl
respect
classif
regress
tree
cart
model
use
identifi
independ
variabl
predict
mortal
outcom
invas
ventil
renal
replac
therapi
also
chosen
outcom
cart
model
direct
correl
sever
mortal
possibl
variabl
extract
build
cart
tabl
total
refer
retriev
upon
screen
regard
inclus
exclus
criteria
section
eleven
refer
includ
data
extract
analysi
addit
refer
identifi
manual
search
total
studi
elig
select
shown
figur
studi
includ
patient
case
report
case
seri
observ
studi
saudi
arabia
countri
origin
patient
studi
rest
franc
greec
qatar
detail
characterist
patient
includ
articl
present
tabl
eight
studi
use
specif
antivir
treatment
studi
use
support
treatment
includ
invas
ventil
prone
posit
renal
replac
therapi
vasopressor
corticosteroid
immunoglobulin
oseltamivir
omrani
et
al
use
specif
antivir
treatment
support
treatment
specif
antivir
treatment
ifn
ribavirin
sever
other
includ
tenofovir
emtricitabin
lopinavir
ritonavir
among
patient
recruit
report
detail
inform
regard
baselin
characterist
comorbid
treatment
outcom
surviv
time
subsequ
use
perform
univari
analysi
kaplanmei
surviv
curv
tabl
found
support
inform
hemodialysi
depend
appear
higher
frequenc
ifn
group
supportiveonli
group
p
convers
renal
replac
therapi
vasopressor
use
often
supportiveonli
group
ifn
group
p
tabl
qualiti
case
report
case
seri
assess
use
care
checklist
tabl
found
support
inform
contain
introduct
describ
import
case
abstract
main
introduct
section
demograph
symptom
patient
signific
qualiti
observ
studi
assess
use
metric
tool
tabl
found
support
inform
three
score
describ
studi
design
characterist
patient
popul
inclus
criteria
method
qualiti
mer
diagnosi
howev
none
studi
describ
data
collect
method
assign
method
patient
exclus
criteria
interpret
treatment
antivir
drug
oseltamivir
report
studi
ifn
ifn
combin
ribavirin
common
remedi
use
studi
ifn
use
studi
n
use
dose
treatment
ribavirin
administr
start
load
dose
follow
subsequ
dose
studi
load
dose
mg
studi
mg
one
studi
alghamdi
et
al
subsequ
dose
howev
variabl
among
studi
rang
mgd
frequenc
administr
ribavirin
dose
per
day
studi
dose
per
day
anoth
studi
durat
treatment
ribavirin
also
variabl
rang
day
subsequ
oral
ribavirin
dose
adjust
accord
calcul
creatinin
clearanc
studi
howev
durat
treatment
day
load
dose
mg
use
studi
similar
regardless
creatinin
clearanc
tabl
found
support
inform
addit
treatment
ifn
ribavirin
treatment
regimen
shalhoub
et
al
includ
treatment
tenofovir
regard
mortal
studi
case
includ
metaanalysi
pool
proport
mortal
studi
includ
mer
patient
figur
patient
receiv
ifn
treatment
mortal
rate
high
spite
receiv
treatment
ribavirin
plu
ifn
likewis
mortal
rate
high
patient
receiv
support
treatment
n
statist
signific
mortal
differ
compar
mortal
group
p
signific
differ
death
surviv
patient
chronic
renal
diseas
crd
model
tool
cart
identifi
crd
best
paramet
predict
mortal
figur
perform
decis
tree
tool
classifi
mortal
outcom
accuraci
sensit
specif
ppv
npv
addit
treatment
inotrop
exhibit
best
paramet
predict
renal
replac
therapi
outcom
figur
perform
decis
tree
tool
classifi
renal
replac
therapi
outcom
accuraci
sensit
specif
ppv
npv
signific
result
detect
regard
invas
ventil
outcom
surviv
time
admiss
death
compar
ifntreat
n
nonifn
support
care
n
patient
case
die
within
day
hospit
admiss
figur
one
femal
case
treat
ifn
elimin
analysi
patient
remain
intub
origin
studi
end
howev
met
death
criteria
thu
includ
differ
group
statist
signific
p
figur
longer
surviv
period
onset
death
simpli
attribut
durat
onset
admiss
systemat
review
highlight
signific
age
period
ill
onset
start
antivir
therapi
mer
case
prognost
assess
result
reveal
younger
age
evid
differ
ifn
treatment
support
treatment
mer
patient
term
mortal
ribavirin
ifn
combin
might
promis
effect
therapi
start
promptli
advers
effect
monitor
care
random
control
trial
requir
assess
possibl
concern
prognost
factor
delay
treatment
older
age
accompani
comorbid
hypertens
dm
chronic
kidney
diseas
dialysi
depend
associ
wors
outcom
high
fatal
serious
newli
emerg
diseas
limit
number
avail
case
believ
urgent
need
largescal
clinic
trial
efficaci
antivir
treatment
merscov
infect
author
declar
compet
interest
orcid
ahm
abdelmotaleb
ghazi
http
nguyen
tien
huy
http
